JP2020530465A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530465A5 JP2020530465A5 JP2020507090A JP2020507090A JP2020530465A5 JP 2020530465 A5 JP2020530465 A5 JP 2020530465A5 JP 2020507090 A JP2020507090 A JP 2020507090A JP 2020507090 A JP2020507090 A JP 2020507090A JP 2020530465 A5 JP2020530465 A5 JP 2020530465A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- protein
- composition according
- tfr
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023107814A JP2023123757A (ja) | 2017-08-10 | 2023-06-30 | トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 |
| JP2025090730A JP2025120209A (ja) | 2017-08-10 | 2025-05-30 | トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762543658P | 2017-08-10 | 2017-08-10 | |
| US62/543,658 | 2017-08-10 | ||
| US201762583314P | 2017-11-08 | 2017-11-08 | |
| US62/583,314 | 2017-11-08 | ||
| USPCT/US2018/018371 | 2018-02-15 | ||
| PCT/US2018/018371 WO2018152326A1 (en) | 2017-02-17 | 2018-02-15 | Engineered transferrin receptor binding polypeptides |
| PCT/US2018/046337 WO2019033046A1 (en) | 2017-08-10 | 2018-08-10 | AFFINITY BASED METHODS FOR USING TRANSFERRIN RECEPTOR BINDING PROTEINS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023107814A Division JP2023123757A (ja) | 2017-08-10 | 2023-06-30 | トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020530465A JP2020530465A (ja) | 2020-10-22 |
| JP2020530465A5 true JP2020530465A5 (enExample) | 2021-09-16 |
Family
ID=65272509
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507090A Pending JP2020530465A (ja) | 2017-08-10 | 2018-08-10 | トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 |
| JP2020506964A Active JP7280241B2 (ja) | 2017-08-10 | 2018-08-10 | 操作されたトランスフェリン受容体結合ポリペプチド |
| JP2023107814A Pending JP2023123757A (ja) | 2017-08-10 | 2023-06-30 | トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 |
| JP2025090730A Pending JP2025120209A (ja) | 2017-08-10 | 2025-05-30 | トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020506964A Active JP7280241B2 (ja) | 2017-08-10 | 2018-08-10 | 操作されたトランスフェリン受容体結合ポリペプチド |
| JP2023107814A Pending JP2023123757A (ja) | 2017-08-10 | 2023-06-30 | トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 |
| JP2025090730A Pending JP2025120209A (ja) | 2017-08-10 | 2025-05-30 | トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US20200289627A1 (enExample) |
| EP (2) | EP3665194A4 (enExample) |
| JP (4) | JP2020530465A (enExample) |
| CN (2) | CN111094336A (enExample) |
| CA (2) | CA3072035A1 (enExample) |
| DK (1) | DK3665192T5 (enExample) |
| ES (1) | ES2956062T3 (enExample) |
| FI (1) | FI3665192T3 (enExample) |
| HR (1) | HRP20231118T1 (enExample) |
| HU (1) | HUE063021T2 (enExample) |
| LT (1) | LT3665192T (enExample) |
| MD (1) | MD3665192T2 (enExample) |
| PL (1) | PL3665192T3 (enExample) |
| PT (1) | PT3665192T (enExample) |
| RS (1) | RS64584B1 (enExample) |
| SI (1) | SI3665192T1 (enExample) |
| SM (1) | SMT202300347T1 (enExample) |
| TW (1) | TWI821197B (enExample) |
| WO (2) | WO2019032955A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2932759T3 (es) | 2017-02-17 | 2023-01-25 | Denali Therapeutics Inc | Polipéptidos de unión al receptor de transferrina diseñados |
| MA50746A (fr) | 2017-10-02 | 2020-08-12 | Denali Therapeutics Inc | Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive |
| TW202017947A (zh) * | 2018-08-22 | 2020-05-16 | 美商戴納立製藥公司 | 抗her2 多肽及其使用方法 |
| CN113614110B (zh) | 2019-02-20 | 2025-03-25 | 戴纳立制药公司 | 抗trem2抗体及其使用方法 |
| AU2020411480B2 (en) | 2019-12-23 | 2023-12-21 | Denali Therapeutics Inc. | Progranulin variants |
| AU2021208482B2 (en) * | 2020-01-13 | 2025-12-11 | Denali Therapeutics Inc. | Anti-TREM2 antibodies and methods of use thereof |
| BR112022016232A2 (pt) * | 2020-02-19 | 2022-11-16 | Denali Therapeutics Inc | Proteínas biespecíficas anti-her2 manipuladas |
| CR20230178A (es) | 2020-10-14 | 2023-07-26 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas |
| WO2023034409A1 (en) | 2021-09-01 | 2023-03-09 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
| WO2023128702A1 (ko) * | 2021-12-31 | 2023-07-06 | 주식회사 아임뉴런 | 뇌혈관장벽 투과성 융합 단백질 및 이의 용도 |
| CN120112164A (zh) | 2022-07-29 | 2025-06-06 | 瑞泽恩制药公司 | 包含修饰的转铁蛋白受体基因座的非人动物 |
| AU2023314808A1 (en) | 2022-07-29 | 2025-03-20 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
| JP2025525792A (ja) | 2022-07-29 | 2025-08-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | トランスフェリン受容体１に対して再標的化されるウイルス粒子 |
| AU2023312978A1 (en) | 2022-07-29 | 2025-03-20 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:payload fusions and methods of use thereof |
| EP4634218A2 (en) * | 2022-12-16 | 2025-10-22 | Denali Therapeutics Inc. | Methods and compositions related to engineered transferrin receptor-binding molecules |
| AU2024317483A1 (en) | 2023-07-28 | 2026-01-29 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease |
| AR133384A1 (es) | 2023-07-28 | 2025-09-24 | Regeneron Pharma | Anti-tfr:esfingomielinasa ácida para el tratamiento de la deficiencia de esfingomielinasa ácida |
| WO2025137213A1 (en) | 2023-12-20 | 2025-06-26 | Denali Therapeutics Inc. | Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereof |
| WO2026052654A1 (en) * | 2024-09-03 | 2026-03-12 | F. Hoffmann-La Roche Ag | Cytokine receptor agonist |
| WO2026052652A1 (en) * | 2024-09-03 | 2026-03-12 | F. Hoffmann-La Roche Ag | Cytokine receptor agonist |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1212365A2 (en) * | 1999-08-30 | 2002-06-12 | New York University School Of Medicine | Crystal structures of domains of receptor protein tyrosine kinases and their ligands |
| ES2354653T3 (es) * | 2006-08-01 | 2011-03-16 | Pieris Ag | Muteínas de lipocalina lacrimal y procedimientos para obtener las mismas. |
| CN110251668A (zh) * | 2010-11-30 | 2019-09-20 | 霍夫曼-拉罗奇有限公司 | 低亲和力血脑屏障受体抗体及其用途 |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| KR20190121874A (ko) * | 2012-08-29 | 2019-10-28 | 에프. 호프만-라 로슈 아게 | 혈액 뇌 장벽 셔틀 |
| SG11201509566RA (en) * | 2013-05-20 | 2015-12-30 | Genentech Inc | Anti-transferrin receptor antibodies and methods of use |
| CA2932547C (en) * | 2014-01-06 | 2023-05-23 | F. Hoffmann-La Roche Ag | Monovalent blood brain barrier shuttle modules |
| SG10201912019WA (en) * | 2014-05-22 | 2020-02-27 | Pieris Pharmaceuticals Gmbh | Novel specific-binding polypeptides and uses thereof |
| EP3218411B1 (en) * | 2014-11-14 | 2022-01-12 | Ossianix, Inc. | Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use |
| JP6993228B2 (ja) * | 2014-11-19 | 2022-03-03 | ジェネンテック， インコーポレイテッド | 抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法 |
| WO2016081643A1 (en) * | 2014-11-19 | 2016-05-26 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
| PE20221007A1 (es) * | 2015-06-24 | 2022-06-15 | Hoffmann La Roche | Anticuerpos anti-receptor de transferrina con afinidad disenada |
| AR106189A1 (es) * | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| US10457717B2 (en) * | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
-
2018
- 2018-08-10 EP EP18843180.3A patent/EP3665194A4/en active Pending
- 2018-08-10 MD MDE20200637T patent/MD3665192T2/ro unknown
- 2018-08-10 TW TW107128067A patent/TWI821197B/zh active
- 2018-08-10 EP EP18756531.2A patent/EP3665192B1/en active Active
- 2018-08-10 CN CN201880053177.4A patent/CN111094336A/zh active Pending
- 2018-08-10 RS RS20230817A patent/RS64584B1/sr unknown
- 2018-08-10 JP JP2020507090A patent/JP2020530465A/ja active Pending
- 2018-08-10 LT LTEPPCT/US2018/046199T patent/LT3665192T/lt unknown
- 2018-08-10 WO PCT/US2018/046199 patent/WO2019032955A1/en not_active Ceased
- 2018-08-10 ES ES18756531T patent/ES2956062T3/es active Active
- 2018-08-10 PT PT187565312T patent/PT3665192T/pt unknown
- 2018-08-10 PL PL18756531.2T patent/PL3665192T3/pl unknown
- 2018-08-10 HR HRP20231118TT patent/HRP20231118T1/hr unknown
- 2018-08-10 CA CA3072035A patent/CA3072035A1/en active Pending
- 2018-08-10 JP JP2020506964A patent/JP7280241B2/ja active Active
- 2018-08-10 WO PCT/US2018/046337 patent/WO2019033046A1/en not_active Ceased
- 2018-08-10 SI SI201830986T patent/SI3665192T1/sl unknown
- 2018-08-10 DK DK18756531.2T patent/DK3665192T5/da active
- 2018-08-10 FI FIEP18756531.2T patent/FI3665192T3/fi active
- 2018-08-10 SM SM20230347T patent/SMT202300347T1/it unknown
- 2018-08-10 CN CN201880063660.0A patent/CN111148757B/zh active Active
- 2018-08-10 CA CA3072051A patent/CA3072051A1/en active Pending
- 2018-08-10 HU HUE18756531A patent/HUE063021T2/hu unknown
-
2020
- 2020-02-05 US US16/782,984 patent/US20200289627A1/en not_active Abandoned
- 2020-02-05 US US16/782,669 patent/US20200369746A1/en not_active Abandoned
-
2023
- 2023-02-08 US US18/166,223 patent/US20230381286A1/en active Pending
- 2023-06-30 JP JP2023107814A patent/JP2023123757A/ja active Pending
- 2023-09-08 US US18/464,025 patent/US20240024432A1/en not_active Abandoned
-
2025
- 2025-05-30 JP JP2025090730A patent/JP2025120209A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530465A5 (enExample) | ||
| Ma et al. | Macrophage depletion reduced brain injury following middle cerebral artery occlusion in mice | |
| Reichenbach et al. | Inhibition of Stat3‐mediated astrogliosis ameliorates pathology in an Alzheimer's disease model | |
| Burwinkel et al. | Intravenous injection of beta-amyloid seeds promotes cerebral amyloid angiopathy (CAA) | |
| Kempf et al. | Anti-inflammatory mechanisms and therapeutic opportunities in myocardial infarct healing | |
| Stahl et al. | Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications | |
| JP2015509097A5 (enExample) | ||
| Leonhardt et al. | Trigger mechanisms of secondary sclerosing cholangitis in critically ill patients | |
| Liu et al. | Clearance of amyloid-beta in Alzheimer’s disease: shifting the action site from center to periphery | |
| McClung et al. | A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab | |
| Anand et al. | Tailored delivery of analgesic ziconotide across a blood brain barrier model using viral nanocontainers | |
| JP7204235B2 (ja) | 活性型α－シヌクレインに結合する抗体 | |
| Dalkara | Pericytes: a novel target to improve success of recanalization therapies | |
| McIntee et al. | In vivo differential brain clearance and catabolism of monomeric and oligomeric Alzheimer's Aβ protein | |
| JP2018503357A5 (enExample) | ||
| JP2018524370A5 (ja) | 抗ピログルタミン酸化アミロイドβヒト化抗体 | |
| Meier et al. | Pinpointing brain TREM2 levels in two mouse models of Alzheimer’s disease | |
| WO2016201434A2 (en) | Stable formulations of humanized anti-tau antibody | |
| Yogendrakumar et al. | Emerging adjuvant thrombolytic therapies for acute ischemic stroke reperfusion | |
| Marelli et al. | The P42 peptide and Peptide-based therapies for Huntington’s disease | |
| Tamura et al. | The F (ab′) 2 fragment of an Aβ-specific monoclonal antibody reduces Aβ deposits in the brain | |
| Pluta et al. | Factors in creepy delayed neuronal death in hippocampus following brain ischemia–reperfusion injury with long-term survival | |
| Banks et al. | Passage of murine scrapie prion protein across the mouse vascular blood–brain barrier | |
| An et al. | A brain-shuttled antibody targeting alpha synuclein aggregates for the treatment of synucleinopathies | |
| Chappa et al. | Characteristics of Substance P Transport Across the Blood–Brain Barrier: Chappa, Audus, and Lunte |